Study finds a more effective treatment option for HER2 mutant metastatic breast cance
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable.
More... |
All times are GMT -7. The time now is 12:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021